Targeting Kynurenine 3-Monooxygenase (KMO): Implications for Therapy in Huntington's Disease
Keywords: 3-hydroxykynurenine; AMPA; Alzheimer's disease; CCL5; Drosophila; Elongation factor 3; Excitotoxicity; GABA; HD Pathology; HD neostriatum; HEAT; Huntington's disease; INDOL1; KYNA; Neuropathology; PR65/A; Parkinson's disease; QUIN; RANTES; Saccharomyces cerevisiae; TDO; TOR1); amyotrophic lateral sclerosis; axon-sparing; bradykinesia; cerebral malaria; chorea; dystonia; kynurenic acid; kynurenine 3-monooxygenase (KMO); kynurenine pathway; locomotor; microglia; multiple sclerosis; neurodegeneration; neuronal asphyxia; polyQ; quinolinic acid; schizophrenia; serotonin/melatonin; tryptophan
Document Type: Research Article
Publication date: 2010-12-01
- CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in neurological and CNS disorders. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.